Global Longevity BioTech Market Size and Forecast Report 2026-2030 | Capitalize on 10.7% CAGR as Insilico Medicine, Calico, and Altos Labs Lead the Industry

Dublin, Oct. 21, 2026 -- "Longevity BioTech Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The global longevity biotech market is experiencing rapid expansion as investment in healthy aging, regenerative medicine, and advanced therapeutics continues to increase. The market is projected to grow from $20.9 billion in 2025 to $23.2 billion in 2026, representing a compound annual growth rate (CAGR) of 11%. This growth reflects rising investment in anti-aging research, the increasing prevalence of age-related chronic diseases, expanding interest in extending healthspan, greater biotechnology venture capital funding, and wider adoption of genetic and cellular therapies.

Looking ahead, the longevity biotech market is forecast to reach $34.82 billion by 2030, growing at a CAGR of 10.7%. Market expansion is expected to be supported by stronger regenerative medicine pipelines, growing partnerships between pharmaceutical businesses and longevity biotechnology firms, increasing demand for gene-based therapies, and the wider use of personalized wellness diagnostics. Collaboration among research institutes, clinical organizations, and biotechnology developers is also accelerating the commercialization of technologies designed to address biological aging.

Key longevity biotech market trends include advances in cellular rejuvenation, gene editing, stem-cell-based regeneration, senolytic drug development, and epigenetic reprogramming. Artificial intelligence and multi-omics platforms are also helping researchers identify therapeutic targets, analyze complex biological data, and improve the speed and precision of drug discovery. These developments are creating new opportunities across healthcare, biotechnology, pharmaceuticals, preventive health, and personalized wellness.

The growing global emphasis on extending healthy lifespan and preventing age-related decline remains a major market driver. Aging populations are increasing demand for preventive healthcare, early diagnostics, and medical technologies that can preserve physical and cognitive function. Longevity biotechnology companies are responding by developing therapies, testing platforms, and personalized interventions that target aging-related biological processes and reduce the risk of chronic disease.

Demographic change further strengthens the long-term outlook for the sector. According to the World Health Organization, the worldwide population aged 60 and older is expected to increase from 1.1 billion in 2023 to 1.4 billion by 2030 and reach 2.1 billion by 2050. This increase highlights the scale of future demand for longevity therapeutics, biological-age testing, regenerative treatments, and preventive health programs.

Biological-age diagnostics are emerging as an important area of innovation. Companies are developing DNA methylation-based epigenetic tests that support longitudinal monitoring and provide insights into aging across different biological systems. These tools can strengthen clinical research, product validation, personalized health assessment, and measurement of intervention outcomes. In March 2023, Elysium Health introduced the TIME-A longitudinal research study linked to its Index epigenetic test. The initiative combines participant surveys with epigenetic data to support aging research and deliver system-level biological-age insights.

Strategic acquisitions are also reshaping the competitive environment. In June 2025, Juvenescence Limited acquired Ro5 Inc. for an undisclosed amount. The transaction is intended to strengthen Juvenescence's drug discovery capabilities through the integration of Ro5's artificial intelligence platform. The technology analyzes complex biological datasets to identify and optimize potential therapeutic candidates for age-related diseases, supporting faster early-stage development.

North America was the largest region in the longevity biotech market in 2025, while Asia-Pacific is expected to record the fastest growth during the forecast period. The market spans Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy, and Spain.

Markets Covered:
1) By Service: Longevity Consultation; Biological Age Testing; Preventive Health Programs
2) By Therapeutic Approach: Senolytics; Gene Therapies; Regenerative Medicine; Metabolic Modulators; Mitochondrial Therapies
3) By Technology: Gene Editing Technology; Artificial Intelligence And Machine Learning; Stem Cell And Regenerative Medicine; Multi-Omics Analysis Platforms; Advanced Drug Screening
4) By Application: Healthcare; Biotech; Pharmaceuticals; Wellness; Aging Population
5) By End User: Clinics; Hospitals; Research Institutes; Direct-To-Consumer

Subsegments:
1) By Longevity Consultation: Initial Health Assessment; Personalized Longevity Planning; Lifestyle And Nutrition Counseling; Risk Assessment And Mitigation Planning; Follow-Up Longevity Monitoring; Genetic And Epigenetic Review
2) By Biological Age Testing: DNA Methylation Age Testing; Telomere Length Testing; Metabolic Age Assessment; Inflammatory Biomarker Testing; Hormonal Age Profiling; Organ-Specific Aging Analysis
3) By Preventive Health Programs: Chronic Disease Prevention Programs; Nutrition And Diet Optimization Plans; Fitness And Mobility Enhancement Programs; Stress And Sleep Management Programs; Immune Strengthening Protocols; Personalized Supplementation Programs

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Report Attribute	Details
No. of Pages	250
Forecast Period	2026-2030
Estimated Market Value (USD) in 2026	$23.2 Billion
Forecasted Market Value (USD) by 2030	$34.82 Billion
Compound Annual Growth Rate	10.7%
Regions Covered	Global

The companies featured in this Longevity BioTech market report include:

• Insilico Medicine Inc.
• Calico Life Sciences LLC
• Retro Biosciences Inc.
• Altos Labs Inc.
• LyGenesis Inc.
• NewLimit Inc.
• Halia Therapeutics Inc.
• Life Biosciences Inc.
• BioAge Labs Inc.
• Rubedo Life Sciences Inc.
• Juvenescence Limited
• Cambrian BioPharma Inc.
• Elevian Inc.
• Oisin Biotechnologies Inc.
• Rejuvenate Bio Inc.
• Unity Biotechnology Inc.
• Cleara Biotech B.V.
• Junevity Inc.
• Liv Longevity Labs
• Genflow Biosciences plc
• Centenara Labs AG

For more information about this report visit https://www.researchandmarkets.com/r/y37vj6

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.